Company: EDSA
Filing Date: 2025-07-25
Form Type: S-3
Source: 0001171843-25-004721
Chunk: 8

Company: Edesa Biotech, Inc.
Filing Date: 2025-07-25
Form: S-3
Chunk 8
---
 prospectus supplement, the net proceeds from the sale of the securities will be used for working capital and general corporate purposes. When particular securities are offered, the prospectus supplement relating to that offering will set forth our intended use of the net proceeds received from the sale of those securities we sell. Pending the application of the net proceeds for these purposes, we expect to invest the proceeds in short-term, interest-bearing instruments or other investment-grade securities.

| 5 |

<div align='center'>THE SECURITIES WE MAY OFFER</div>

The descriptions of the securities contained in this prospectus, together with the applicable prospectus supplements, summarize all of the material terms and provisions of the various types of securities that we may offer. We will describe in the applicable prospectus supplement relating to any securities the particular terms of the securities offered by that prospectus supplement. If we indicate in the applicable prospectus supplement, the terms of the securities may differ from the terms we have summarized below. We may also include in the prospectus supplement information about material Canadian or United States federal income tax considerations relating to the securities, and the securities exchange, if any, on which the securities will be listed.

We may sell from time to time, in one or more offerings:

| ● | common shares;                                                                      |
| ● | preferred shares;                                                                   |
| ● | debt securities;                                                                    |
| ● | subscription rights to purchase common shares, preferred shares or debt securities; |
| ● | warrants to purchase common shares or preferred shares; and                         |
| ● | units consisting of any combination of the securities listed above.                 |

In this prospectus, we refer to the common shares, preferred shares, debt securities, subscription rights, warrants and units collectively as “securities.” The total dollar amount of all securities that we may sell will not exceed $150,000,000.

If we issue debt securities at a discount from their original stated principal amount, then, for purposes of calculating the total dollar amount of all securities issued under this prospectus, we will treat the initial offering price of the debt securities as the total original principal amount of the debt securities.

This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement.

| 6 |

<div align='center'>DESCRIPTION OF CAPITAL SHARES</div>

We are authorized to issue an unlimited
number of common shares and preferred shares, no par value. As of July 25, 2025, there were 7,029,750 common shares outstanding